All-sky Medium Energy Gamma-ray Observatory: Exploring the Extreme Multimessenger Universe

The All-sky Medium Energy Gamma-ray Observatory (AMEGO) is a probe class mission concept that will provide essential contributions to multimessenger astrophysics in the late 2020s and beyond. AMEGO combines high sensitivity in the 200 keV to 10 GeV energy range with a wide field of view, good spectral resolution, and polarization sensitivity. Therefore, AMEGO is key in the study of multimessenger astrophysical objects that have unique signatures in the gamma-ray regime, such as neutron star mergers, supernovae, and flaring active galactic nuclei. The order-of-magnitude improvement compared to previous MeV missions also enables discoveries of a wide range of phenomena whose energy output peaks in the relatively unexplored medium-energy gamma-ray band

Electrocatalizadores para pilas de combustible de membrana de intercambio prot\uf3nico.

Electrocatalizadores para pilas de combustible de membrana de intercambio prot\uf3nico. Procedimiento de obtenci\uf3n de un material de carbono mesoporoso (SMC) que comprende: la adici\uf3n de s\uedlice coloidal a un precursor polim\ue9rico de carbono; el curado t\ue9rmico; el carbonizado del compuesto obtenido; lavado del compuesto carbonizado con \ue1cido fluorh\ueddrico (HF) o NaOH; y la oxidaci\uf3n del material lavado. Adem\ue1s la invenci\uf3n se refiere a un catalizador para pilas de combustible de electrolito polim\ue9rico basado en la utilizaci\uf3n del nuevo soporte carbonoso mesoporoso

A comparison of European countries FBDG in the light of their contribution to tackle diet-related health inequalities

Background: The purpose of this article is to report on a comparative analysis of the official food-based dietary guidelines (FBDG) that were applicable in 2015 in 25 EU Member States. We assess FBDG in relation to the main guidelines established by the FAO/WHO, the EURODIET project and the EFSA, with a particular focus on identifying strengths and limitations of current FBDG in Europe towards addressing diet-related health inequalities.Methods: This is a review research, in which a mixed-methods sequenced procedure was utilized. In each EU country key informants, including sociologists, economists, dietitians and nutritionists were asked to provide data regarding: (i) current dietary guidelines and national health priorities, (ii) model of health promotion currently available, (iii) results of the latest food consumption survey. All documents were reviewed by the coordinating team. Full data were analysed by two nutritionists, using a tabulated sheet to organize and compare the results.Results: While all countries have national FBDG, the level of detail and quality varies substantially with regard to: time of last update; availability of recommendations for specific target groups; specification of frequency and portion size; the graphical representation; recommended amounts and limits of foods consumed; and recommendations regarding physical activity.Conclusions: European countries have great opportunities to improve FBDG to better serve Public Health policy through a more consistent foundation of how these guidelines are developed, the inclusion of different population subgroups as a target for recommendations and the implementation of monitoring systems

Procedimiento para incrementar la conductividad el\ue9ctrica de un material de carbono mesoporoso ordenado y material obtenibile a partir de dicho procedimiento

Procedimiento para incrementar la conductividad el\ue9ctrica de un material de carbono mesoporoso ordenado y material obtenible a partir de dicho procedimiento. La presente invenci\uf3n se refiere a un procedimiento para incrementar la conductividad el\ue9ctrica de un material de carbono mesoporoso ordenado (CMK-3) obtenido mediante la t\ue9cnica de nanomoldeo, donde dicho procedimiento comprende tratar t\ue9rmicamente en atm\uf3sfera inerte dicho material de carbono mesoporoso ordenado. Asimismo, es objeto de la invenci\uf3n el material obtenible a partir de dicho procedimiento, un procedimiento para la obtenci\uf3n de un electrocatalizador a partir de dicho material y su uso para la obtenci\uf3n de un ensamblaje membrana/electrod

Protein disulfide isomerase A3-specific Th1 effector cells infiltrate colon cancer tissue of patients with circulating anti-protein disulfide isomerase A3 autoantibodies

To investigate novel colorectal cancer (CRC)-associated antigens that could be targets of humoral or cellular responses, we analyzed the reactivity of serum from a long-surviving CRC patient (for more than 100 months of follow-up) in clinical remission, by serologic proteome analysis. Two-dimensional Western blotting (2D-WB) and mass spectrometry analysis revealed a strong reactivity of this serum against protein disulfide isomerase A3 (PDIA3). Anti-PDIA3 antibodies are not a diagnostic marker of CRC, 2D-WB and Luminex analysis revealed that they were equally present in about 10% of sera from healthy subjects and CRC patients. Kaplan-Meier analysis of survival in CRC patient cohort, after 48 months of follow-up, showed a trend of higher survival in patients with increased levels of autoantibodies to PDIA3. Therefore, the interplay between the presence of these antibodies and T-cell response was investigated. Peripheral blood T cells from CRC patients with high immunoglobulin G (IgG) reactivity to PDIA3 also secreted interferon gamma (IFN-gamma) when stimulated in vitro with recombinant PDIA3, whereas those from CRC with low IgG reactivity to PDIA3 did not. PDIA3-pulsed dendritic cells efficiently induced proliferation and IFN-gamma production of autologous CD4(+) and CD8(+) T cells. Finally, ex vivo analysis of tumor infiltrating T lymphocytes from CRC patients with autoantibodies to PDIA3 revealed that PDIA3-specific Th1 effector cells accumulated in tumor tissue. These data indicate that the presence of autoantibodies to PDIA3 favors the development of an efficient and specific T-cell response against PDIA3 in CRC patients. These results may be relevant for the design of novel immunotherapeutic strategies in CRC patients